Arbutus Biopharma Corporation Stock News

Equities research analysts expect Arbutus Biopharma Co. (NASDAQ:ABUS) to report sales of $3.39 million for the current quarter, Zacks reports. Two analysts have issued estimates for Arbutus Biopharmas earnings, with the highest sales estimate coming in at $3.47 million and the lowest estimate coming in at $3.30 million. Arbutus Biopharma posted sales of $2.39 million []

MENDHAM, N.J. and WARMINSTER, Pa., Dec. 14, 2021 (GLOBE NEWSWIRE) -- Antios Therapeutics, Inc. (“Antios”) and Arbutus Biopharma Corporation (Nasdaq: ABUS) today announced that the first patient has been dosed in a triple combination treatment in patients with chronic hepatitis B virus (HBV) infection. A single cohort in the ongoing Antios Phase 2a SAVE-1 (Sustained Anti-Viral Efficacy) clinical trial will evaluate a triple combination of Antios’ proprietary active site polymerase inhibitor nucleotide (ASPIN), ATI-2173, Arbutus’ proprietary GalNAc delivered RNAi therapeutic, AB-729, and tenofovir disoproxil fumarate (TDF), a nucleotide reverse transcriptase inhibitor.

5 penny stocks analysts say are a buy right now with hefty price targets. The post Penny Stocks To Buy According To 5 Analysts With 55%-246% Targets appeared first on Penny Stocks to Buy, Picks, News

Brokerages expect Arbutus Biopharma Co. (NASDAQ:ABUS) to post $3.39 million in sales for the current quarter, Zacks Investment Research reports. Two analysts have provided estimates for Arbutus Biopharma’s earnings. The highest sales estimate is $3.47 million and the lowest is $3.30 million. Arbutus Biopharma reported sales of $2.39 million in the same quarter last year, […]

In the last trading session, 7.06 million shares of the Arbutus Biopharma Corporation (NASDAQ:ABUS) were traded, and its beta was 2.60. Most recently the company’s share price was $4.14, and it changed around -$0.17 or -3.94% from the last close, which brings the market valuation of the company to $581.59M. ABUS currently trades at a … Arbutus Biopharma Corporation (NASDAQ: ABUS): Would You Buy Today? Read More »

(RTTNews) - Arbutus Biopharma Corp. (ABUS) and Qilu Pharmaceutical announced an exclusive licensing agreement and strategic partnership to develop and commercialize AB-729 for the treatment or prevention of hepatitis B in mainland China, Hong Kong, Macau and Taiwan. As per the agreement, Arbutus would receive a $40 million upfront payment and

Arbutus Biopharma Corp (NASDAQ: ABUS) shares are trading higher after the company announced it received a $40M upfront payment from Qilu to commercialize AB-729 in Asia. William Collier, President a

Got $5 to spend on penny stocks? Take a look at these four for your watchlist The post Got $5 to Spend on Penny Stocks?

NEW YORK , Dec. 10, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for LCID, ET, ARDX, IINN, and ABUS. Full story available on Benzinga.com

There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 The post Eye-popping stocks: Arbutus Biopharma Corporation (NASDAQ:ABUS 4.11%), CVS Health Corporation (NYSE:CVS 4.52%) appeared first on Stocks Equity .

Arbutus Biopharma Co. (NASDAQ:ABUS) shares were up 4.6% during mid-day trading on Thursday . The stock traded as high as $4.42 and last traded at $4.33. Approximately 48,112 shares were traded during mid-day trading, a decline of 99% from the average daily volume of 3,942,938 shares. The stock had previously closed at $4.14. A number []

Are these Reddit penny stocks on your watchlist right now? The post 4 Penny Stocks That Are Trending on Reddit Right Now and Why appeared first on Penny Stocks to Buy, Picks, News and Information | Pe

Brokerages predict that Arbutus Biopharma Co. (NASDAQ:ABUS) will post earnings of ($0.18) per share for the current fiscal quarter, Zacks Investment Research reports. Two analysts have made estimates for Arbutus Biopharmas earnings, with the highest EPS estimate coming in at ($0.16) and the lowest estimate coming in at ($0.19). Arbutus Biopharma posted earnings per share []

Analysts are bullish on these penny stocks in 2021. Should you be?

Arbutus Biopharma Corporation (NASDAQ: ABUS ) has identified several molecules that inhibit the SARS-CoV-2 nsp5 main protease (Mpro), a validated target for treating COVID-19 and potential future coronavirus outbreaks. In April 2021, Arbutus, X-Chem Inc , and Proteros biostructures GmbH entered a discovery Full story available on Benzinga.com